Active	Status	Sponsor type	Region	Phase	Filter
50 Active 22 Inactive 72 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

13 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Li
NCT06697522: Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children	Completed	3	148	RoW	Atropine Sulfate, Investigational product, Placebo, Blank Solvent	Ocumension Therapeutics (Suzhou) Co., Ltd, Beijing Children's Hospital	Myopia	10/23	03/24
NCT05793892: Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults	Completed	3	286	RoW	Lidocaine tetracaine cream, test drug:CU-30101, control drug:Pliaglis	Cutia Therapeutics（Wuxi）Co.,Ltd	Analgesia	08/23	10/23
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time	Completed	3	928	Europe, Canada, Japan, US, RoW	Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec	Eli Lilly and Company	Diabetes, Type 2 Diabetes	04/24	04/24
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight	Recruiting	3	600	Europe, Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	OSA, Overweight or Obesity	11/26	01/27
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease	Recruiting	3	400	RoW	SJP-0132, Placebo	Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd.	Dry Eye	07/25	08/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities	Active, not recruiting	3	3000	Europe, Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Obesity, Overweight, Overweight or Obesity	07/25	07/27
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight	Active, not recruiting	3	2300	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea	04/26	05/26
JSKN003-102, NCT05744427: Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors Dec 2024 - Dec 2024 : Results for HER2-low, U/M BC	Recruiting	1/2	725	RoW	JSKN003	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Advanced Solid Tumor	12/24	12/26
OPAL-1, NCT05970497: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors	Recruiting	1/2	140	US	KB707, Opdualag	Krystal Biotech, Inc.	Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma	07/26	07/26
TQB2858-Ⅰ-06, NCT05068921: A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy	Recruiting	1	40	RoW	TQB2858 injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Advanced Cervical Cancer	05/23	07/23
NCT06678581: SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects	Completed	1	70	RoW	SAP-001, SAP-001 tablet, Placebo, placebo tablet	Shanton Pharma Co., Ltd.	Gout, Hyperuricemia	12/23	01/24
DEVIF-I, NCT06230822: Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)	Recruiting	1	9	RoW	VUM02 Injection, Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells Injection	Wuhan Optics Valley Vcanbiopharma Co., Ltd.	Idiopathic Pulmonary Fibrosis	01/25	12/26
OASIS, NCT06063317: A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors	Recruiting	1	33	US	CF33-CD19 IT, CF33-CD19 IV, Blinatumomab, Blincyto	Imugene Limited	Solid Tumor, Adult	06/27	05/29
Wang, Luo-wei
No trials found